• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Edwin Choy, MD, PhD


  • Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, Cote GM, Wagner AJ, Morgan JA, Sirisawad M, Mani C, Hornicek FJ, Duan Z, Demetri GD.
    Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Cancer. 2015 Apr 15;121(8):1223-30.
  • Osaka E, Kelly AD, Spentzos D, Choy E, Yang X, Shen JK, Yang P, Mankin HJ, Hornicek FJ, Duan Z.
    MicroRNA-155 expression is independently predictive of outcome in chordoma.
    Oncotarget. 2015 Mar 16.
  • Yang X, Feng Y, Gao Y, Shen J, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z.
    NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Gynecol Oncol. 2015 Apr;137(1):134-42.
  • Yang X, Iyer AK, Singh A, Choy E, Hornicek FJ, Amiji MM, Duan Z.
    MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
    Sci Rep. 2015;5:8509.
  • Lee HJ, Yoon C, Park do J, Kim YJ, Schmidt B, Lee YJ, Tap WD, Eisinger-Mathason TS, Choy E, Kirsch DG, Simon MC, Yoon SS.
    Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature.
    Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):621-30.
  • Choy E, MacConaill LE, Cote GM, Le LP, Shen JK, Nielsen GP, Iafrate AJ, Garraway LA, Hornicek FJ, Duan Z.
    Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1.
    PLoS ONE. 2014;9(7):e101283.
  • Choy E.
    Sarcoma after 5 years of progression-free survival: Lessons from the French Sarcoma Group.
    Cancer. 2014 Jun 18.
  • Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z.
    Programmed Cell Death Ligand 1 Expression in Osteosarcoma.
    Cancer Immunol Res. 2014 Apr 21.
  • Cheney MD, Giraud C, Goldberg SI, Rosenthal DI, Hornicek FJ, Choy E, Mullen JT, Chen YL, Delaney TF.
    MRI surveillance following treatment of extremity soft tissue sarcoma.
    J Surg Oncol. 2014 May;109(6):593-6.
  • Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, Nielsen GP, Yang C, Zhang C, Mankin H, Hornicek FJ, Borger DR, Duan Z.
    Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma.
    PLoS ONE. 2014;9(4):e93996.
  • Duan Z, Shen J, Yang X, Yang P, Osaka E, Choy E, Cote G, Harmon D, Zhang Y, Nielsen GP, Spentzos D, Mankin H, Hornicek F.
    Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma.
    J Orthop Res. 2014 May;32(5):695-701.
  • Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH.
    Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Eur J Cancer. 2014 Mar;50(5):981-6.
  • Choy E, Allen Jacobs I.
    Biosimilar safety considerations in clinical practice.
    Semin Oncol. 2014 Feb;41 Suppl 1:S3-14.
  • Jia B, Choy E, Cote G, Harmon D, Ye S, Kan Q, Mankin H, Hornicek F, Duan Z.
    Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.
    Cancer Lett. 2014 Jan 1;342(1):104-12.
  • Cote GM, Choy E.
    Update in treatment and targets in Ewing sarcoma.
    Hematol Oncol Clin North Am. 2013 Oct;27(5):1007-19.
  • Zhang L, Guo S, Schwab JH, Nielsen GP, Choy E, Ye S, Zhang Z, Mankin H, Hornicek FJ, Duan Z.
    Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.
    PLoS ONE. 2013;8(9):e75851.
  • Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Kobayashi W, Szymonifka J, Yeap BY, Chen YL, Harmon DC, Choy E, Yoon SS, Raskin KA, Hornicek FJ, Nielsen GP.
    β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Oncologist. 2013;18(9):1043-9.
  • Cote GM, Choy E.
    Role of epigenetic modulation for the treatment of sarcoma.
    Curr Treat Options Oncol. 2013 Sep;14(3):454-64.
  • Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I.
    Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
    Lancet Oncol. 2013 Aug;14(9):901-8.
  • Hong NJ, Hornicek FJ, Harmon DC, Choy E, Chen YL, Yoon SS, Nielsen GP, Szymonifka J, Yeap BY, Delaney TF, Mullen JT.
    Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year single institution retrospective study.
    Eur J Cancer. 2012 Oct 20.
  • Yang W, Liu X, Choy E, Mankin H, Hornicek FJ, Duan Z.
    Targeting hedgehog-GLI-2 pathway in osteosarcoma.
    J Orthop Res. 2012 Sep 11.
  • Mullen JT, Delaney TF, Kobayashi WK, Szymonifka J, Yeap BY, Chen YL, Rosenberg AE, Harmon DC, Choy E, Yoon SS, Raskin KA, Petur Nielsen G, Hornicek FJ.
    Desmoid Tumor: Analysis of Prognostic Factors and Outcomes in a Surgical Series.
    Ann Surg Oncol. 2012 Sep 11.
  • Duan Z, Zhang J, Choy E, Harmon D, Liu X, Nielsen P, Mankin H, Gray NS, Hornicek FJ.
    Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation.
    Clin Cancer Res. 2012 Sep 1;18(17):4580-8.
  • Liu X, Nielsen GP, Rosenberg AE, Waterman PR, Yang W, Choy E, Sassi S, Yang S, Harmon DC, Yang C, Schwab JH, Kobayashi E, Mankin HJ, Xavier R, Weissleder R, Duan Z, Hornicek FJ.
    Establishment and characterization of a novel chordoma cell line: CH22.
    J Orthop Res. 2012 Oct;30(10):1666-73.
  • George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.
    Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    J Clin Oncol. 2012 Jul 1;30(19):2401-7.
  • Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD.
    Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial.
    Cancer. 2012 May 17.
  • Duan Z, Li X, Huang H, Yuan W, Zheng SL, Liu X, Zhang Z, Choy E, Harmon D, Mankin H, Hornicek F.
    Synthesis and Evaluation of (2-(4-Methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) Isomers To Reverse Multidrug Resistance in Cancer.
    J Med Chem. 2012 Mar 22.
  • Mullen JT, Kobayashi W, Wang JJ, Harmon DC, Choy E, Hornicek FJ, Rosenberg AE, Chen YL, Spiro IJ, Delaney TF.
    Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.
    Cancer. 2011 Dec 16.
  • Choy E, Hornicek F, Macconaill L, Harmon D, Tariq Z, Garraway L, Duan Z.
    High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
    Cancer. 2011 Oct 17.
  • Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H, Hornicek FJ.
    MicroRNA-199a-3p is Down Regulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration.
    Mol Cancer Ther. 2011 Jun 10.
  • Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z.
    Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.
    Anticancer Res. 2011 Apr;31(4):1115-23.
  • Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI, Ebb DH, Choy E, Raskin KA, Liebsch N, Hornicek FJ, Delaney TF.
    Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma.
    Cancer. 2011 Mar 29.
  • Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.
    Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Anti Cancer Drugs. 2011 Mar 10.
  • Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H, Duan Z.
    ROCK1 as a potential therapeutic target in osteosarcoma.
    J Orthop Res. 2011 Mar 8.
  • Susa M, Choy E, Liu X, Schwab JH, Hornicek FJ, Mankin H, Duan Z.
    Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking.
    Mol Cancer Ther. 2010 Dec;9(12):3342-50.
  • Guo Y, Nemeth JA, O'Brien C, Susa M, Liu X, Zhang Z, Choy E, Mankin H, Hornicek FJ, Duan Z.
    Effects of Siltuximab on the IL-6 Induced Signaling Pathway in Ovarian Cancer.
    Clin Cancer Res. 2010 Dec 1;16(23):5759-69.
  • Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF.
    Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas.
    Int J Radiat Oncol Biol Phys. 2010 Oct 5.
  • Yang C, Hornicek FJ, Wood KB, Schwab JH, Choy E, Mankin H, Duan Z.
    Blockage of Stat3 With CDDO-Me Inhibits Tumor Cell Growth in Chordoma.
    Spine. 2010 Aug 15;35(18):1668-75.
  • Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, Milane L, Amiji MM, Duan Z.
    Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.
    PLoS ONE. 2010;5(5):e10764.
  • Yang C, Hornicek FJ, Wood KB, Schwab JH, Choy E, Iafrate J, Rosenberg A, Nielsen GP, Xavier RJ, Mankin H, Duan Z.
    Characterization and analysis of human chordoma cell lines.
    Spine. 2010 Jun 1;35(13):1257-64.
  • Ryu K, Choy E, Yang C, Susa M, Hornicek FJ, Mankin H, Duan Z.
    Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis.
    J Orthop Res. 2010 Jul;28(7):971-8.
  • Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ, Duan Z.
    Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
    BMC Cancer. 2010;10:187.
  • Yoon SS, Chen YL, Kirsch DG, Maduekwe UN, Rosenberg AE, Nielsen GP, Sahani DV, Choy E, Harmon DC, Delaney TF.
    Proton-Beam, Intensity-Modulated, and/or Intraoperative Electron Radiation Therapy Combined with Aggressive Anterior Surgical Resection for Retroperitoneal Sarcomas.
    Ann Surg Oncol. 2010 Jun;17(6):1515-29.
  • Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z.
    Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.
    Cancer Chemother Pharmacol. 2010 May 12.
  • Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, Choy E, Yang C, Mankin H, Hornicek FJ.
    Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma.
    Cancer Lett. 2010 Jul 28;293(2):220-9.
  • Duan Z, Choy E, Nielsen GP, Rosenberg A, Iafrate J, Yang C, Schwab J, Mankin H, Xavier R, Hornicek FJ.
    Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression.
    J Orthop Res. 2010 Jun;28(6):746-52.
  • Yang C, Ji D, Weinstein EJ, Choy E, Hornicek FJ, Wood KB, Liu X, Mankin H, Duan Z.
    The Kinase Mirk is a Potential Therapeutic Target in Osteosarcoma.
    Carcinogenesis. 2010 Apr;31(4):552-8.
  • Susa M, Choy E, Yang C, Schwab J, Mankin H, Hornicek F, Duan Z.
    Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
    J Biomol Screen. 2010 Mar;15(3):287-96.
  • Choy E, Digumarthy SR, Koplin SA.
    Case records of the Massachusetts General Hospital. Case 36-2009. A 23-year-old man with cough, hoarseness, and abnormalities on chest imaging.
    N Engl J Med. 2009 Nov 19;361(21):2080-7.
  • Duan Z, Choy E, Hornicek FJ.
    NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.
    PLoS ONE. 2009;4(10):e7415.
  • Yang C, Schwab JH, Schoenfeld AJ, Hornicek FJ, Wood KB, Nielsen GP, Choy E, Mankin H, Duan Z.
    A novel target for treatment of chordoma: signal transducers and activators of transcription 3.
    Mol Cancer Ther. 2009 Sep;8(9):2597-605.
  • Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ.
    ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.
    PLoS ONE. 2009;4(9):e6967.
  • Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ.
    Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
    Mol Cancer Ther. 2009 Aug;8(8):2122-30.
  • Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, Nielsen P, Iafrate J, Delaney T, Yoon S, Choy E, Harmon D, Raskin K, Yang C, Mankin H, Springfield D, Hornicek F, Duan Z.
    Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.
    Anticancer Res. 2009 Jun;29(6):1867-71.
  • Maduekwe UN,Hornicek FJ,Springfield DS,Raskin KA,Harmon DC,Choy E,Rosenberg AE,Nielsen GP,DeLaney TF,Chen YL,Ott MJ,Yoon SS.
    Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas.
    Ann Surg Oncol. 2009 May;16(5):1356-63.
  • Choy E,Yelensky R,Bonakdar S,Plenge RM,Saxena R,De Jager PL,Shaw SY,Wolfish CS,Slavik JM,Cotsapas C,Rivas M,Dermitzakis ET,Cahir-McFarland E,Kieff E,Hafler D,Daly MJ,Altshuler D.
    Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines.
    PLoS Genet. 2008 Nov;4(11):e1000287.
  • Duan Z,Choy E,Jimeno JM,Cuevas Cdel M,Mankin HJ,Hornicek FJ.
    Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
    Cancer Chemother Pharmacol. 2009 May;63(6):1121-9.
  • Duan Z,Weinstein EJ,Ji D,Ames RY,Choy E,Mankin H,Hornicek FJ.
    Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer.
    Mol Cancer Ther. 2008 Aug;7(8):2377-85.
  • Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, Ivanov IE, Philips MR.
    Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi.
    Cell. Jul 9;98;1:69-80.